Published in final edited form as:

Rev Physiol Biochem Pharmacol. 2016 ; 170: 37–66. doi:10.1007/112_2015_5002.

CFTR: A new horizon in the pathomechanism and treatment of pancreatitis

Péter Hegyi^{1,2}, Michael Wilschanski³, Shmuel Muallem⁴, Gergely Lukacs⁵, Miklós Sahin-Tóth⁶, Aliye Uc⁷, Michael A. Gray⁸, Zoltán Rakonczay^{1,9}, and József Maléth^{1,2}

¹First Department of Medicine, University of Szeged, Szeged, Hungary

²MTA-SZTE Translational Gastroenterology Research Group, Szeged, Hungary

³Pediatric Gastroenterology Unit, Hadassah Medical Center, Hebrew University, Jerusalem, Israel

⁴National Institute of Dental and Craniofacial Research, Bethesda, MD, USA

⁵Department of Physiology, McGill University, Montreal, Canada

⁶Department of Molecular and Cell Biology, Boston University Henry M. Goldman School of Dental Medicine, Boston, MA, USA

⁷Department of Pediatrics, University of Iowa, Carver College of Medicine, Iowa City, IA, USA

⁸Institute for Cell & Molecular Biosciences, University Medical School, Newcastle University, Newcastle upon Tyne, UK

⁹Department of Pathophysiology, University of Szeged, Szeged, Hungary

Abstract

Cystic fibrosis transmembrane conductance regulator (CFTR) is an ion channel that conducts chloride and bicarbonate ions across epithelial cell membranes. Mutations in the *CFTR* gene diminish the ion channel function and lead to impaired epithelial fluid transport in multiple organs such as the lung and the pancreas resulting in cystic fibrosis. Heterozygous carriers of *CFTR* mutations do not develop cystic fibrosis but exhibit increased risk for pancreatitis and associated pancreatic damage characterized by elevated mucus levels, fibrosis and cyst formation. Importantly, recent studies demonstrated that pancreatitis causing insults, such as alcohol, smoking or bile acids strongly inhibit CFTR function. Furthermore, human studies showed reduced levels of CFTR expression and function in all forms of pancreatitis. These findings indicate that impairment of CFTR is critical in the development of pancreatitis; therefore, correcting CFTR function could be the first specific therapy in pancreatitis. In this review, we summarize recent advances in the field and discuss new possibilities for the treatment of pancreatitis.

Corresponding author: Prof. Dr. Peter Hegyi, Doctor of the Hungarian Academy of Sciences, First Department of Medicine, University of Szeged, Koranyi fsr. 8–10, SZEGED, H6720, Hungary, TEL: +3662545200, FAX: +3662545185, MOBILE: +36703751031, hegyi.peter@med.u-szeged.hu.

Conflict of interest statement: the authors have no conflict of interest to declare

Keywords

pancreas; cystic fibrosis; epithelial transport; pancreatitis; CFTR

I. Basics of CFTR

a. Biosynthesis and degradation

The cystic fibrosis transmembrane conductance regulator (CFTR) protein is a cyclic AMP (cAMP)-regulated chloride (Cl^-)/bicarbonate (HCO_3^-) channel, expressed in the apical plasma membrane (PM) of secretory epithelia in the airways, pancreas, intestine, reproductive organs and exocrine glands [1]. CFTR consists of two homologous halves, each containing a hexa-helical membrane spanning domain (MSD1 and MSD2) and a nucleotide binding domain (NBD1 and NBD2) (Figure 1). The two halves are connected by the R domain [2]. The NBDs contain conserved ATP-binding sequences: Walker A and B motifs, classifying CFTR as a member of the ATP-binding cassette (ABC) transporter family. Structural, biochemical and functional evidence suggest that the two NBD domains interact and the ATP-binding site of one NBD is complemented by the ABC signature motif of the other [2].

While NBD1 folds largely co-translationally, the native fold of NBD2 as well as CFTR are attained post-translationally [3]. Assembly of MSD1, NBD1, R domain and MSD2 is necessary and sufficient to form the minimal folding unit of CFTR [4]. These and other observations support the cooperative domain folding model and ensure the dynamic conformational coupling between the cytosolic NBDs and the pore-forming MSDs in the native molecule and provide a structural explanation for the cooperative domain *unfolding*, caused by cystic fibrosis (CF) mutations [4].

Despite interactions with several cytosolic and endoplasmic reticulum (ER) chaperones (heat shock proteins Hsp70 and Hsp90, co-chaperones; Hdj2 [DNAJ1], HsBp1, Hop and p23, small Hsps, calnexin and calreticulin), only 30–60% of the newly synthesized nascent CFTR attains folded conformation, presumably due to the metastable nature of NBD1 and NBD2, the slow kinetics of domain assembly, and the highly efficient ER quality control [5]. The conformational maturation of CFTR is promoted by cytosolic ATP and the conjugation of N-glycan chains at the ER [3]. Approximately 40–70% of the synthesized core-glycosylated channels are eliminated in the ER by the ubiquitin-proteasome system (UPS). The native CFTR that bypasses multiple checkpoints in the ER is packaged into COPII coated transport vesicles and undergoes complex-glycosylation in the *medial*-Golgi before being delivered to the PM (Figure 2). [6].

At the PM, CFTR is constitutively internalized followed by efficient recycling from the endosomes back to the PM, which renders the channel metabolically stable (half-life [$T_{1/2}$] of ~12–14h). In contrast, the most common mutation, p.F508del has several fold accelerated PM turnover ($T_{1/2}$ ~2h) relative to its wild-type counterpart similar to other conformationally damaged PM proteins [7]. Damaged PM proteins are usually removed following their ubiquitination that confers accelerated internalization, impeded recycling and preferential

sorting towards lysosomal degradation [7]. Thus, it is plausible to assume that wild-type CFTR harboring various structural defects due to cellular stress and aging, similarly to that of the p.F508del, is recognized by components of the protein homeostasis (proteostasis) machinery and is targeted by ubiquitin- and ESCRT-dependent mechanism for lysosomal proteolysis. Multiple E3 ubiquitin-ligases (CHIP, gp78, NEDD4 and c-Cbl) in cooperation with chaperones/co-chaperones (Hsc70, Hsp90 and co-chaperones e.g. Hdj2 [DNAJ1], Bag1, HOP and Aha1) have been implicated in the removal of damaged p.F508del and wild-type CFTR from the PM [8]. Supporting the ubiquitin-dependent degradation of wild-type CFTR, the de-ubiquitinating enzyme (DUB) Usp10 stabilizes the channel at the PM by facilitating its recycling [9].

Presently, six major classes of mutations are distinguished based on their cellular pathophysiology (Figure 2). [10]. Severely reduced cell surface CFTR expression is associated with (a) Class I mutations which include frameshift, splicing or nonsense mutations that introduce premature termination codons, (b) Class II mutations, which lead to misfolding and impaired protein biogenesis at the ER, (c) Class V mutations which result in reduced synthesis due to promoter or splicing abnormalities, and (d) Class VI mutations that destabilize the channel in post-ER compartments and/or at the PM. CFTR function is selectively compromised by Class III and IV mutations that can impair the gating and channel pore conductance, respectively.

b. Physiological functions

In epithelial tissues, transport of anions by CFTR represents the rate-limiting step for anion (Cl^- and HCO_3^-) secretion, which ultimately controls transepithelial fluid secretion and hence hydration of the epithelial luminal surfaces (Figure 3). In addition, through CFTR's ability to conduct HCO_3^- , as well as to regulate $\text{Cl}^-/\text{HCO}_3^-$ exchangers belonging to the SLC26A family [11], CFTR also controls the pH of the secreted fluid. CFTR, therefore, controls both the amount and composition of epithelial secretions such as pancreatic juice, sweat, and airway surface liquid which play vital physiological roles in the innate defense of the lungs, digestion of foods, reproduction and body temperature regulation.

A major interest in the channel stems from the fact that loss of function mutations in the gene encoding CFTR result in the inherited disease CF, one of the most common, life-shortening diseases in the Caucasian population. At the other end of the spectrum, and affecting far more people globally, overactive CFTR causes clinically important secretory diarrheas induced by toxins from pathogenic bacteria, such as *Vibrio cholerae*.

CFTR gating is regulated by the R domain which contains multiple PKA and PKC phosphorylation sites and which physically interacts with NBD1 [12–15] (Figure 4). Uniquely, CFTR uses the energy of ATP binding and hydrolysis to drive ligand-induced conformational changes in the protein that lead to the regulated opening and closing (gating) of the channel 'pore'. In this way, CFTR gating tightly 'regulates' the flow of anions in and out of the cell, with the anion being transported down its prevailing electrochemical gradient by a purely facilitative diffusional process.

For the channel to open, it must be first phosphorylated by PKA, and then ATP must also bind to CFTR's NBDs. Extensive biochemical, electrophysiological, structural and molecular modelling studies support a scheme whereby following PKA phosphorylation of the R domain, CFTR gating is induced by ATP binding and dimerization of its two NBDs [16]. This event is transmitted to the MSDs that form the 'pore' of the channel through a complex and dynamic interaction between their cytoplasmic linker loops (coupling helices) and the dimerised NBDs [17]. ATP (ligand) binding therefore drives the structural rearrangement of the transmembrane helices that result in the opening of the channel pore (Figure 4). CFTR is also an ATPase [18]; hydrolysis of ATP and the release of ADP and Pi disrupt the NBD dimer thereby terminating channel opening. Further rounds of channel opening can continue if ATP binds again but the gating cycle can be stopped by the removal of phosphate groups from the R domain by intracellular phosphatases [13, 14]. It is apparent then that CFTR gating is a complex process involving a variety of intracellular factors that regulate multiple inter- and intra-domain interactions within the protein.

c. Genetic mutations

Genetic variations in *CFTR* that affect membrane levels or channel activity lead to various pancreatic phenotypes [19]. CF with pancreatic insufficiency develops when both *CFTR* alleles harbor "severe" mutations resulting in loss of CFTR function. CF can also present with pancreatic sufficiency provided a severe mutation on one *CFTR* allele is compounded by a "mild" or "variable" mutation on the other allele, with some preservation of CFTR function. Whereas CF patients with pancreatic insufficiency do not develop acute pancreatitis, about 15–20% of pancreatic sufficient CF patients may present with acute or recurrent acute pancreatitis. The combination of a severe and a mild *CFTR* mutation can also result in idiopathic recurrent acute or chronic pancreatitis and some of these patients exhibit abnormal sweat Cl⁻ or nasal potential difference (NPD) tests. Thus, a clear diagnostic line between CF-related pancreatitis and CFTR-related idiopathic chronic pancreatitis cannot be drawn. Finally, heterozygous carrier status for a CF-causing mutation increases the risk for recurrent acute and chronic pancreatitis. The discovery that *CFTR* variants are overrepresented in chronic pancreatitis was first published in 1998 [20] and was confirmed by a large number of follow-up studies [21–24]. However, many of these were limited by the use of small cohorts, the lack of screening unaffected controls and incomplete analysis of the *CFTR* gene resulting in some controversy regarding the extent of disease risk; the role of non-CF causing variants and the significance of common polymorphic variants and their associated haplotypes. Recently published analyses of large German (660 cases), French (253 cases) and North-American (984 cases) cohorts [25–27] confirmed earlier findings and strengthened the consensus on the role of *CFTR* variants in chronic pancreatitis.

Heterozygous carriers of the severe p.F508del CF mutation are overrepresented in patients with chronic pancreatitis (~7%) relative to healthy controls (~3%). Thus, CF carrier status confers a small risk for chronic pancreatitis (odds ratio ~2.5). Other types of severe mutations are less frequently found in chronic pancreatitis but seem to be associated with similar disease risk as p.F508del.

Heterozygous carriers of the mild CF mutation p.R117H are enriched among cases with chronic pancreatitis (~2.5%) relative to controls (~0.6%). Mutation p.R117H appears to cause comparable or even slightly higher risk (odds ratio ~4) than the severe p.F508del mutation, for reasons that are not readily apparent. With respect to the CF phenotype, the penetrance of p.R117H is influenced by the length of the poly-T tract in intron-8 (legacy numbering); however, such conclusion cannot be drawn for chronic pancreatitis on the basis of available data. Other mild or variable CF mutations are rare in chronic pancreatitis but are likely to confer similar risk as p.R117H.

Compound heterozygous genotypes composed of severe and mild *CFTR* alleles are strong risk factors for chronic pancreatitis and may be considered causative [25]. The odds ratio of 16 described for a large German cohort is likely a conservative estimate for disease risk [26]. Due to some uncertainty which mutations can be considered mild, the reported frequency of compound heterozygotes in chronic pancreatitis cases has been highly variable. After exclusion of T5 allele carriers (see below), neutral mutations as given in the CFTR2 database (<http://cftr2.org>), and mutations of unknown clinical significance, the prevalence of compound heterozygotes was 1.4% in a German cohort [26] and 2.4% in a French cohort [25]. Compound heterozygosity for two mild *CFTR* mutations is rare and probably increases pancreatitis risk strongly, although solid data are lacking.

Non-CF-causing *CFTR* variants are not overrepresented in chronic pancreatitis cases. A recent study suggested that some non-CF-causing variants (e.g. p.R75Q, p.L997F) may be risk factors for chronic pancreatitis due to a selective defect in HCO₃⁻ conductance [27]. While functional measurements seem to support this contention, a genetic association between these variants and chronic pancreatitis cannot be confirmed [25–27].

Common polymorphic *CFTR* alleles do not modify pancreatitis risk. There are two adjacent polymorphic regions (poly-T and poly-TG tracts) in intron-8 which can alter inclusion of exon-9 (legacy numbering) during splicing [28–30]. A short poly-T tract (c.1210-12T[5], legacy name T5) in combination with a longer poly-TG tract (c.1210-34TG[12], legacy name TG12) results in more transcripts lacking exon-9 that give rise to inactive CFTR protein. A T5 allele combined with a severe *CFTR* mutation may cause CF and increases the penetrance of the mild p.R117H mutation. Studies on smaller cohorts reported enrichment of the T5 allele in chronic pancreatitis [21, 23, 24, 31], however, more recent analyses on larger cohorts did not find such overrepresentation [26, 27]. When analyzed separately, the distribution of the TG12 allele between chronic pancreatitis cases and controls was also equal [26]. Whether or not the T5-TG12 complex allele confers a small risk in chronic pancreatitis remains to be determined. Curiously, small but measurable differences were reported for the distribution of the TG10 and TG11 alleles between chronic pancreatitis cases and controls, either analyzed separately or as part of conserved haplotypes [26, 32]. In two studies, TG10 appeared to increase disease risk slightly while TG11 seemed to be protective. Since the two studies used overlapping cohorts and the results clearly contradict the expected functional effects of the TG10 and TG11 tracts, cautious interpretation of the findings is warranted until independent confirmation (Table 1).

Chronic pancreatitis is a complex genetic disease and mutations in different risk genes are often found in cases. Trans-heterozygosity of *CFTR* variants with mutations in *PRSS1*, *SPINK1* and *CTRC* were reported [21, 24, 26, 27]. The combined effects of multiple pathogenic mutations results in strongly amplified disease risk; best documented for the co-occurrence of *SPINK1* and *CFTR* mutations. There is no compelling evidence for epistasis between *SPINK1* and *CFTR* mutations; the two susceptibility genes seem to act independently in determining the pancreatitis phenotype [26]. *CFTR* mutations can also contribute to the increased clinical penetrance of anatomical risk factors for chronic pancreatitis such as pancreas divisum [33].

II. Pancreatic damage in CF

a. Experimental observations in CF models

A CF animal model that recapitulates the human findings provides a powerful tool to study disease pathophysiology and design therapies. There are four main CF animal models with pancreatic manifestations (Table 2).

Mice—CF mouse models are generated by disrupting the endogenous *Cftr* gene in embryonic stem cells using the homologous recombination technology [34, 35]. In general, intestinal disease is the hallmark of CF mouse models with minimal or no pathological changes in the pancreas. The lack of pancreatic disease may be due to developmental/structural differences in the rodent pancreas, relatively low *CFTR* expression with higher expression of alternative anion channels, modifier genes and/or the short life span of CF mice [36, 37]. This model is an important tool to study the intestinal disease in CF without the confounding effects of pancreatic disease.

Rats—Recently, a CF rat model was generated using zinc-finger endonuclease technology [37]. Animals demonstrated *CFTR* channel dysfunction in airway epithelia, histological abnormalities in the ileum and absence of vas deference, all characteristics of CF. The CF rats did not have any evidence of pancreatic involvement within the first 6 weeks of life.

Pigs—The CF porcine model was generated by disrupting the *CFTR* gene in pig fibroblasts followed by somatic cell nuclear transfer [38]. CF pigs have multisystem disease that recapitulates the human disease and exhibit a severe pancreatic phenotype. The pancreatic lesions start *in utero* and progress over time in this model [39], in concordance with the previous autopsy studies of humans with CF [40]. The newborn CF pig pancreas has acinar cell loss, duct proliferation, dilated acini/ducts with zymogen-like material, expansion of interlobular connective tissue, and scattered inflammatory cell aggregates [38, 39]. Mucous cell metaplasia is a late finding. In older animals, the exocrine pancreatic lesions progress and pancreas is mostly replaced by fat and fibrosis. The islets are morphologically intact, but functionally abnormal [41]. As in humans [42], the pancreatic fluid is acidic, low in volume and high in protein and concentrated in CF pigs at birth [43]. The proinflammatory, complement cascade, proapoptotic, and profibrotic pathways are activated in CF pig pancreas, and likely contribute to the destructive process [39].

Ferrets—CF ferrets were generated using homologous recombination as described for CF pigs. The pancreatic lesions are mild in CF ferrets at birth compared to CF pigs (dilation of most acini and ductules with inspissated, eosinophilic zymogen secretions). Interestingly, the exocrine pancreas undergoes rapid destruction over the first month of life [44], leading to acinar loss, fibrosis and pancreatic insufficiency. Even though CF ferrets have only mild exocrine pancreatic disease at birth, they still manifest significant problems in glucose tolerance and insulin secretion [45]. Fifteen percent of ferrets are pancreatic sufficient and have normal pancreas, suggesting a possible role of genetic modifiers. The CF ferret model is emerging as an important tool to investigate the early pathogenesis of CF-related diabetes.

Zebrafish—Recently a zebrafish model of CF has been described [46]. The development of the pancreas is normal initially, followed by rapid destruction during larval life via a process that involves neutrophil infiltration. The zebrafish model along with pig and ferret models underlines the importance of inflammation in pancreatic damage.

Phenotypic differences among the various CF models may be due to species-specific CFTR processing, genetic and environmental influences, and effects of other ion channels. These animal models offer a unique opportunity to study the pathogenesis of CF pancreatic disease and various therapeutic approaches.

b. Clinical characterization of pancreatic function in CF

The consequences of mutations in the *CFTR* gene have been demonstrated by pancreatic function studies which show that CF patients have low-flow secretions with a high protein concentration, which can precipitate in the duct lumina causing obstruction and damage. These changes begin *in utero* and after delivery the process of small duct obstruction leading to large duct obstruction continues. At birth and for several months afterwards, there is a release into the blood stream of proteins originating in the pancreas. An example of this is immunoreactive trypsinogen (IRT) which serves as the basis for the neonatal screening test for CF. Interestingly, despite the wholesale destruction of the exocrine pancreas occurring, the infant is asymptomatic; the reason for this is yet to be determined. Eventually, this process results in severe inflammatory changes, obstruction of ducts by mucus and calcium containing debris, the destruction of acini and generalized fibrosis. Contrary to popular belief that the pancreas is entirely non-functioning at birth, the high IRT does show that some exocrine pancreatic tissue is still present and this may have a bearing on possible small molecule therapy targeted at the remainder of the pancreas which may rescue enough tissue to cause viability of the remaining pancreas.

One of the most remarkable observations is that genetic factors exquisitely influence the degree of pancreatic disease and its rate of progression. Large studies of CF patients resulted in their classification as pancreatic insufficient (PI) or pancreatic sufficient (PS). PI patients comprise of 85% of all CF patients and have maldigestion as defined by evidence of steatorrhea following 72-hour fat balance studies; these patients require pancreatic enzyme replacement therapy with meals. In contrast, PS patients have evidence of pancreatic damage (as shown by the high neonatal IRT test) but retain sufficient endogenous exocrine pancreatic function to sustain normal digestion.

Exocrine pancreatic status is directly linked to genotype [47]. Analysis of particular CFTR mutations in patients with these pancreatic phenotypes (PI vs. PS) revealed two categories of alleles: “severe” and “mild”. Patients homozygous or compound heterozygous for severe alleles belonging to classes I, II, III or VI confer pancreatic insufficiency, whereas a mild class IV or V allele sustains pancreatic function in a dominant fashion, even if the second mutation is severe. This observation finds plausible explanation since all known mild alleles belong to class IV or class V, all of which are (or predicted to be) associated with some residual channel activity at the epithelial apical membranes. However, this classification system is not entirely consistent as there are some Class I mutations with a stop codon at the end of the gene which are in fact PS. A small proportion (2–3%) of patients carrying severe mutations on both alleles are PS at diagnosis but most experience gradual transition from PS to PI. A few missense mutations (e.g. p.G85E) confer a variable pancreatic phenotype.

While mild mutations confer sufficient CFTR function to prevent complete pancreas destruction, many PS patients have reduced exocrine pancreatic capacity and are at an increased risk of pancreatitis. Recurrent acute and chronic pancreatitis is a relatively infrequent complication of CF first reported by Shwachman in 1975 [48]. In this retrospective study only 0.5% of CF patients had pancreatitis. More recently Durno et al. reported that in a cohort of over 1000 patients, followed over a period of 30 years, the incidence was 1.7% [49]. All the patients with pancreatitis were PS. In fact, this subgroup of PS patients appears to be highly susceptible to pancreatitis, since almost 1 in 5 was affected by this complication. In the largest study to date of CF PS patients, Ooi et al. in a seminal paper determined the association between severity of CFTR genotype and the risk of pancreatitis [50]. They examined a large cohort of 277 PS patients from two CF centers of which 62 had well documented pancreatitis. Using a novel pancreatic insufficiency prevalence score, the mutations were divided into three main groups, severe, moderate-severe and mild. They found that the proportion of patients who developed pancreatitis was significantly greater for genotypes in the mild group than the moderate-severe group. Thus, the more mild mutations are associated with increased risk of pancreatitis.

The sweat Cl^- and NPD results in patients with pancreatitis ranged from the values for healthy controls and obligate heterozygotes to the values for CF patients with PS and PI. Median sweat Cl^- and NPD results in patients with no mutation or one mutation were clustered with values obtained in controls and obligate heterozygotes. In contrast, in patients with pancreatitis carrying *CFTR* mutations on both alleles, median ion transport values were intermediate between those of the controls and obligate heterozygotes and those of PS CF patients. Some individual values overlapped with the CF patients and in 21% of patients the diagnosis of CF could be confirmed by abnormal ion channel measurements. Thus, CFTR-mediated ion channel abnormalities are influenced by the number or severity of the CFTR mutations and show a range of abnormalities similar to those in patients with mild or severe classic CF at one extreme and controls and obligate CF heterozygotes on the other. This continuum of electrophysiological abnormalities is not surprising as PS patients have a 17% risk of developing pancreatitis and many of these presentations are in adulthood.

Similar observations have been made in individuals with other CF-like phenotypes, such as men with infertility due to congenital bilateral absence of the vas deferens, who are known

to carry a high frequency of *CFTR* mutations [51]. A relatively large population was examined and similar to the patients with idiopathic pancreatitis a wide range of electrophysiological abnormalities was observed. Abnormalities of *CFTR* function correlated closely with the number and severity of *CFTR* mutations.

III. Effects of pancreatitis inducing factors on *CFTR*

The two most common causes of pancreatitis are alcohol abuse and biliary disease. Since only a small fraction of alcoholics and patients with biliary disease ever develops pancreatitis, it is evident that there is individual susceptibility. Other intrinsic (genetic) and extrinsic factors (e.g. smoking, diet) must also be responsible for the induction of the disease. Furthermore, the importance of nonoxidative ethanol metabolites such as fatty acid ethyl esters as well as cytotoxic fatty acids in acute pancreatitis is now being increasingly recognized [52].

a. Ethanol and fatty acids

The potential role of *CFTR* in pancreatitis is highlighted by the fact that genetic deletion of the apical Cl^- channel increased the severity of alcohol-induced acute pancreatitis in the mouse [53]. Furthermore, patients with alcoholic acute pancreatitis had lower levels of *CFTR* in their pancreatic ducts than control subjects [53]. Using numerous complimentary techniques, we demonstrated that ethanol and fatty acids dose-dependently reduced *CFTR* expression and activity in pancreatic ductal epithelial cells, and inhibited secretion of fluid and HCO_3^- [53, 54]. The oxidative ethanol metabolite acetaldehyde had no such effects. The decrease in *CFTR* expression and plasma membrane density in response to ethanol, palmitoleic acid, or palmitoleic acid ethyl ester administration was caused by accelerated channel turnover at the apical membrane and by aberrant protein folding [53]. The inhibition of *CFTR* by ethanol and fatty acids was associated with a sustained increase in concentrations of intracellular Ca^{2+} and adenosine 3',5'-cyclic (cAMP) monophosphate, depolarization of mitochondrial membranes, and depletion of ATP. Supplementation with ATP almost completely prevented inhibition of *CFTR* activity by ethanol and fatty acids [54]. These findings are in accord with those of Yamamoto et al. [55], who found that 0.3–30 mM ethanol augmented, whereas 100 mM ethanol inhibited secretin-stimulated pancreatic ductal fluid secretion in the guinea pig. Notably, ethanol and fatty acids also evoke a rise in the cytosolic Ca^{2+} concentration and cause depolarization of the mitochondrial membrane and ATP depletion in pancreatic acinar cells, which served as the basis for the above described studies [56, 57].

b. Bile acids

Bile acids are probably the most important components of the bile which are predominantly synthesized in the liver. In humans, the most abundant primary bile acids are chenodeoxycholate and cholate that are conjugated with taurine or glycine.

Pancreatic ductal HCO_3^- secretion is likely to be markedly reduced in patients with biliary acute pancreatitis [58]. Furthermore, under experimental conditions, luminal administration of a low dose of chenodeoxycholate (0.1 mM) stimulated ductal HCO_3^- secretion [59]

which was caused by significantly elevated apical $\text{Cl}^-/\text{HCO}_3^-$ exchange activity in guinea pig ducts [59] and human CFPAC-1 pancreatic duct cells [60]. This stimulatory effect was dependent on Ca^{2+} signaling and CFTR expression; however, it is unlikely to be the result of increased Cl^- conductance, since chenodeoxycholate administration did not activate CFTR Cl^- channel activity in guinea pig pancreatic duct cells. High concentrations (1 mM) of chenodeoxycholate administered from the basolateral or luminal membranes strongly inhibited pancreatic ductal HCO_3^- secretion by causing severe mitochondrial damage [59, 61]. The consequent ATP depletion will affect ATP-dependent transporters like the Na^+/K^+ pump, K^+ channels and CFTR.

c. Smoking

Data on the effects of smoking on CFTR in the pancreas are scarce and contradictory. Pancreatic CFTR mRNA expression in rats exposed to chronic smoke inhalation was increased in animals that developed inflammatory signs upon cigarette smoke exposure compared with animals not showing morphological pancreatic damage [62]. In another study, it has been shown in human subjects that cigarette smoking impairs secretin-stimulated pancreatic ductal secretion which implicates the role of CFTR in the process [63]. Our preliminary data also support this notion since cigarette smoke extract dose-dependently inhibited pancreatic ductal CFTR activity and HCO_3^- secretion in guinea pigs. In fact, the latter results are in accord with those found in other organs such as the airway [64] or intestinal epithelial cells [65]. It seems that CFTR dysfunction due to smoking is primarily an acquired phenomenon and is not affected by the presence of heterozygous *CFTR* mutations [66]. The interpretation of these results, at least with respect to the compounds responsible for the inhibitory effect of CFTR, is difficult as cigarette smoke is estimated to contain more than 7000 chemical components. Nevertheless, several constituents of cigarette smoke have been implicated in the inhibitory effects on CFTR such as acrolein [65], cadmium and manganese [67]. Moreover, these effects were ameliorated by the use of various antioxidants like N-acetylcysteine (a known scavenger of acrolein) or α -tocopherol, suggesting that free radical-induced damage may be responsible for the inhibition of CFTR by cigarette smoke [68].

Interestingly, CFTR is also prominently involved in maintaining the antioxidant glutathione levels in the basal epithelial lining fluid which is also decreased by cigarette smoke [69]. Thus, cigarette smoke may further reduce the antioxidant defense system in a vicious circle. Cigarette smoke exposure has also been reported to induce CFTR internalization and insolubility [70]. Taken together, these data strongly suggest that CFTR could be a therapeutic target in smoking-related diseases. In fact, drugs which increase CFTR function (the CFTR potentiator ivacaftor and the phosphodiesterase 4 inhibitor roflumilast) were found to have beneficial effects on cigarette smoke-induced Cl^- channel inhibition [71, 72].

IV. CFTR dysfunction in pancreatitis

a. Acute pancreatitis

An association between CFTR and the pathogenesis of acute pancreatitis has been presumed for a long time. Impaired CFTR expression in *Cftr*^{-/-} and p.F508del *Cftr* mice resulted in

continuous overexpression of proinflammatory cytokine genes, and more severe acute pancreatitis upon cerulein hyperstimulation [73, 74]. The *Cftr*^{-/-} and p.F508del *Cftr* mice displayed elevated pancreatic edema, neutrophil infiltration and increased mRNA expression of multiple inflammatory mediators. However, induction of acute pancreatitis in *Cftr*^{-/-} mice did not cause acinar cell injury, but rather decreased acinar cell apoptosis with mild exocrine pancreatic insufficiency [73, 74]. Although the authors focused on the alterations in acinar cells function, CFTR is expressed in the pancreatic duct and thus the increased severity of pancreatitis is most likely due to compromised ductal fluid and HCO₃⁻ secretion. Recently, we investigated the role of CFTR in the pathogenesis of acute alcohol-induced pancreatitis and found markedly reduced *in vivo* pancreatic fluid secretion in control and *Cftr*^{-/-} mice treated with ethanol and fatty acids [53]. The *Cftr*^{-/-} mice also displayed more severe acute pancreatitis induced by i.p. injection of ethanol and palmitic acid, including more extensive necrosis [53]. The role of CFTR in acute pancreatitis was further demonstrated in a study examining the scaffolding protein Na⁺/H⁺ exchanger regulatory factor-1 (NHERF-1) in ductal function [75]. Deletion of *Nherf1* reduced expression of CFTR at the apical membrane of the duct and consequently reduced fluid and HCO₃⁻ secretion. Furthermore, it resulted in more severe acute pancreatitis induced by cerulein hyperstimulation and sodium taurocholate in mice [75]. These findings have potential clinical relevance, since we detected markedly decreased CFTR protein and mRNA expression in small pancreatic ducts in tissue samples from patients diagnosed with alcohol-induced acute pancreatitis [53, 75].

Together, these observations suggest that diminished CFTR function, due to either reduced expression or activity, may have crucial importance in the pathogenesis of pancreatitis (Figure 5).

b. Chronic pancreatitis

CFTR dysfunction due to mislocalized protein expression in pancreatic ductal cells has been observed in alcoholic, obstructive, autoimmune and idiopathic chronic pancreatitis [53, 76]. In addition to the direct effects of toxic factors (see section III), indirect mechanisms such as inflammation and necrosis likely contribute to impaired CFTR expression. Importantly, the decreased expression of CFTR observed in chronic pancreatitis is likely the cause of impaired ductal function during pancreatitis [76]. Aberrant expression of CFTR leads to diminished fluid and HCO₃⁻ secretion due to a reduction in the interrelated activity of both the electrogenic 1Cl⁻/2HCO₃⁻ exchanger SLC26A6 and CFTR. This leads to decreased intraluminal pH, decreased washout of the digestive enzymes, and more viscous protein rich ductal fluid [77] (Figure 5). These changes promote the formation of intraluminal protein gel or plugs, which are early histological features of chronic pancreatitis [78]. Intraductal obstruction can lead to pancreatic atrophy, ductal mucinous hyperplasia [79, 80], Goblet-cell metaplasia and perhaps pancreatic stone formation [77].

V. Future perspectives

a. Current treatment options

In the 26 years since the discovery of the gene that causes CF, our understanding of how mutations in *CFTR* cause the varied pathophysiological manifestations of this disease has increased substantially. This knowledge has led to the possibility of new therapeutic approaches aimed at the basic defect. This section will summarize the current state of mutation specific therapy and will focus on orally bioavailable potentiators, correctors and suppressors of *CFTR* gene mutations.

Gene Therapy—After the *CFTR* gene was discovered, there was considerable enthusiasm that gene therapy could be rapidly developed. Indeed, CF has had among the highest number of gene therapy trials. Several vector systems have been tested in human trials including adenoviruses, adeno-associated viruses and cationic lipids. Despite optimism from *in vitro* and initial *in vivo* studies, the trials have hitherto been unsuccessful. The most ambitious gene therapy study in the United Kingdom which randomized 140 patients using a cationic-lipid based vector showed a modest improvement in lung function [81].

Mutation Class Specific Therapy—An alternative to gene therapy are compounds that affect synthesis, trafficking and channel function of CFTR. The classification of *CFTR* mutations shown in Figure 2 enabled researchers to consider targeting distinct groups of patients.

Class I Mutations—This class of mutations include premature termination codons (PTCs) or nonsense codons. Nonsense mutations are responsible for about 10% of CF cases worldwide. However, in Israel nonsense mutations are the cause of CF in most patients [82]. Because such mutations produce little functional CFTR, these patients usually have a severe CF phenotype. The increased understanding of ribosomal function, the process of translation and small molecules that change the interaction between the ribosome and mRNA have led to the identification of several agents that are capable of suppressing PTCs. This has resulted in a novel strategy to treat CF and other genetic disorders caused by PTCs by restoring full length protein expression. Aminoglycoside antibiotics were the first drugs demonstrated to suppress PTCs in disease-causing mutations, allowing the translation of full-length proteins [83]. In 1996, Howard et al. [84] described PTC suppression by the synthetic aminoglycoside geneticin (G418) to restore function in HeLa cells expressing nonsense codons. This pivotal work was extended to four nonsense mutations of the *CFTR* gene that were expressed in the human airway cell line IB3-1. In this study the commonly used aminoglycoside, gentamicin, was incubated with these cells and full length protein was produced [85]. The pre-clinical studies mentioned above have led to a number of clinical trials designed to test both proof of principle and efficacy in patients with genetic diseases caused by PTCs (Table 3).

As stated earlier, about 60% of CF patients in Israel carry PTCs or Class I mutations. Either nasal or intravenous administration of gentamicin improved NPD [86–89]. In all of these studies, there was a variability of response with some patients not responding to gentamicin. Linde et al. [90] showed that this variability may be related to nonsense-mediated mRNA

decay (NMD) - the major machinery evolved to protect against harmful products of nonsense mutations. This is a post-transcriptional translation-dependent surveillance mechanism that prevents the synthesis of proteins carrying PTCs. NMD has been shown to degrade transcripts carrying disease-causing nonsense or frameshift mutations. It is the efficiency of NMD which affects the level of transcripts carrying PTCs, which govern the response to read-through treatment. Response to gentamicin was found only in patients with a higher level of transcripts [90]. Downregulation of NMD in cells carrying the p.W1282X mutation increased the level of CFTR nonsense transcripts and enhanced the CFTR Cl⁻ channel activity in response to gentamicin. This may have a critical clinical correlation in the readthrough of PTCs in various diseases. However, the inconvenience of parenteral administration and the potential for serious toxic effects preclude long-term systemic use of gentamicin for suppression of nonsense mutations.

Another PTC suppressor ataluren was developed through an extensive high throughput screening program using a luciferase based system [91]. The molecule is a 1,2,4 oxadiazole benzoic acid and is reported to interact with mammalian ribosomes in a manner distinct from aminoglycosides. Ataluren does not have antibiotic activity and is orally bioavailable. Studies in myocytes isolated from the *mdx* mouse defined target doses and exposures to rescue dystrophin function. After treatment with ataluren, full-length dystrophin was localized in skeletal and cardiac tissue. In the p.G542X-hCFTR mouse oral and intraperitoneal administration led to detectable full-length CFTR localization at the apical cell membrane of intestinal glandular cells by immuno-fluorescent staining together with improved Cl⁻ conductance as assayed by trans-epithelial ion transport [92]. Correction of CFTR Cl⁻ transport was incomplete. Less than 30% of the short-circuit current that was observed in wild-type mice occurred in the treated CF mice. This suggests that potential clinical benefit would only need partial restoration of protein function. Phase 2 clinical trials show clear improvement of NPDs [93–95], however, a phase 3 clinical trial showed no difference in FEV₁ between the ataluren and placebo group [96] (Table 3). Although the primary outcome was not achieved, the findings are encouraging since it demonstrates a positive effect of disease-modifying therapy using a corrector of CFTR. A confirmatory phase 3 efficacy and safety trial of ataluren in CF patients not receiving chronic inhaled tobramycin (ACT CF trial) is ongoing [96].

Class II Mutations—Class II mutations include the most common mutation, p.F508del. High-throughput screening assays have been used to screen drug libraries and some compounds called correctors have shown promise in improving CFTR processing [97, 98]. One drug, VX-809 (Lumacaftor), an orally bioavailable p.F508del corrector showed moderate improvement in lung function in a phase 2 trial in adults homozygous for p.F508del. This breakthrough may be enhanced by using these compounds with a potentiator for Class II mutations like VX-809, the logic being that the CFTR will be trafficked to the apical surface of the cell and then activated by a potentiator.

The results of a combination therapy have recently been published in the *New England Journal of Medicine*. [99] 1108 patients with CF who were homozygous p.F508del were randomized to lumacaftor, which corrects cellular misprocessing to increase the amount of functional mutated CFTR, with ivacaftor, which increases opening of the channel protein, or

to placebo. Results at 24 weeks showed that patients treated with the combination therapy had a mean improvement of 2.6% to 4.0% in FEV₁, when compared with participants randomized to placebo (P<0.001).

The rate of pulmonary exacerbations in the two trials was 30% to 39% lower among the patients given the combination treatment. This combination therapy has now been approved for CF patients homozygous for p.F508del.

Class III Mutations—Class III mutations require drugs that activate the protein, which is inactive but properly targeted. These compounds are termed potentiators. VX-770 or ivacaftor is a very promising potentiator and is the first FDA approved drug for patients carrying the p.G551D *CFTR* mutation. It was discovered by high throughput screening. *In vitro* studies of the effect of VX-770 on CFTR-mediated Cl[−] secretion were performed on both recombinant cell lines and primary cultures of human bronchial epithelial cells. Van Goor et al. demonstrated that VX-770 increases Cl[−] transport by increasing the open probability of the CFTR channel and increases apical fluid height and ciliary beat frequency [100]. In an important clinical study, orally administered ivacaftor improved CFTR function in patients carrying the p.G551D mutation as measured by sweat Cl[−] concentration and NPD measurements. A phase 3 trial demonstrated significant improvements in FEV₁ from baseline, average weight gain, concentration in sweat Cl[−] and reductions in pulmonary exacerbations [101]. Ivacaftor has shown similar results in patients carrying other Class III mutations.[102].

Class IV and V Mutations—Class IV defects may be susceptible to augmentation of channel function. Possible compounds of potential treatments are flavonoid, compounds like genistein which acts directly on the channel to increase open probability.

Class V mutations often include splicing mutations which produce a variable phenotype. The disease expression is inversely related to the level of correctly spliced transcripts. The effect of over-expression of splicing factors on the level of correctly spliced CFTR transcripts was studied. It has been shown that increasing the level of correctly spliced RNA activated the CFTR channel and restored function. Class IV and V mutations may respond to potentiators like Ivacaftor and these studies are ongoing.

These new developments provide hope that a treatment strategy could be applied to the basic defect rather than downstream manifestations of the disease.

b. Possible treatments in pancreatitis

The protective role of CFTR against alcohol-induced pancreatitis and pancreatic damage has been demonstrated in the *Cftr* knock-out mouse [53]. As a corollary, compelling evidence indicates that CF-causing mutations are associated with an increased prevalence of pancreatitis [103]. Furthermore, the loss-of-function CFTR phenotype, caused by ethanol, palmitic acid and palmitoleic acid, at least partly, can be attributed to attenuated biogenesis, accelerated PM turnover and channel inhibition of CFTR [53]. Thus, restoring the functional cell surface expression of CFTR may partly alleviate the ethanol-induced exocrine pancreas damage.

While the precise molecular mechanism of CFTR downregulation has not been fully elucidated, based on sustained cytosolic $[Ca^{2+}]$ elevation and mitochondrial Ca^{2+} -overload in ethanol or palmitoleic acid exposed cells [53], it is plausible to assume that the folding capacity of molecular chaperone network, confined to the ER and cytosol, is reduced. Depletion of cytosolic [ATP] due to mitochondrial dysfunction upon cellular Ca^{2+} -overload could also contribute to impaired CFTR domain assembly. These events, jointly, elicit the conformational destabilization of newly synthesized CFTR, which leads to the channel accelerated metabolic turnover at the ER and PM [53]. Accordingly, we envision multifaceted therapeutic approaches to alleviate the exocrine pancreas damage in pancreatitis.

Cytosolic Ca^{2+} -overload and the associated mitochondrial dysfunction during ethanol-induced pancreatitis could be attenuated by inhibiting the PM Ca^{2+} entry channels (such as the store operated Ca^{2+} channel Orai1 [104]). Intriguingly, inhibiting PM Ca^{2+} -channels also up-regulates several molecular chaperones, which could be an added advantage in stabilizing CFTR. This treatment had some success in rescuing mutant β -glucocerebrosidase in Gaucher patient-derived fibroblasts [105]. The cytosolic folding capacity of the chaperone systems could be increased also by inducing the unfolded protein response (UPR) or inhibiting the histone deacetylase 7 (HDAC7). Inhibiting the ER-associated degradation and PM mistargeting may help to increase the number of functional channels at the cell surface [106]. Finally, the recently FDA approved pharmacological chaperone, lumacaftor (VX-809) [107] that partially corrects the p.F508del CFTR folding/processing defect and the CFTR gating activator ivacaftor (VX-770) [100], can be considered as potential therapeutics. While both drugs are assumed to directly bind to mutant and wild-type CFTR, lumacaftor has been shown to stabilize the NBD1/MSDs interface in CFTR variants both in the ER and the PM [108, 109]. In contrast, ivacaftor can stimulate the gating of several missense mutations with impaired channel activation upon PKA-mediated phosphorylation [110]. Thus, lumacaftor and ivacaftor may have the potential to revert the conformational and functional defects, respectively, of the ethanol-induced dysfunctional CFTR, a scenario that has to be evaluated experimentally in the future.

Acknowledgments

Our research was supported by the Hungarian Scientific Research Fund (PD115974 (JM), K116634 (PH), NF101116 (ZR)), the Momentum Grant of the Hungarian Academy of Sciences (LP2014-10/2014), the Cystic Fibrosis Canada (GL), NIH R01-DK75302 (GL), the Canadian Institute of Health Research (GL). GL is a recipient of a Canada Research Chair, the NIH DK096327 (AU), NIH DK097820 (AU), NIH DK096518 (John Engelhardt), National Pancreas Foundation Grant (AU), and by NIH/NIDCR intramural grant DE000735 (SM).

References

1. Riordan JR. CFTR function and prospects for therapy. *Annu Rev Biochem.* 2008; 77:701–26. [PubMed: 18304008]
2. Riordan JR. Assembly of functional CFTR chloride channels. *Annu Rev Physiol.* 2005; 67:701–18. [PubMed: 15709975]
3. Lukacs GL, Verkman AS. CFTR: folding, misfolding and correcting the DeltaF508 conformational defect. *Trends Mol Med.* 2012; 18(2):81–91. [PubMed: 22138491]
4. Du K, Lukacs GL. Cooperative assembly and misfolding of CFTR domains in vivo. *Mol Biol Cell.* 2009; 20(7):1903–15. [PubMed: 19176754]

5. Kim SJ, Skach WR. Mechanisms of CFTR Folding at the Endoplasmic Reticulum. *Front Pharmacol.* 2012; 3:201. [PubMed: 23248597]
6. Farinha CM, Matos P, Amaral MD. Control of cystic fibrosis transmembrane conductance regulator membrane trafficking: not just from the endoplasmic reticulum to the Golgi. *FEBS J.* 2013; 280(18):4396–406. [PubMed: 23773658]
7. Okiyonedá T, Apaja PM, Lukacs GL. Protein quality control at the plasma membrane. *Curr Opin Cell Biol.* 2011; 23(4):483–91. [PubMed: 21571517]
8. Apaja PM, Lukacs GL. Protein homeostasis at the plasma membrane. *Physiology (Bethesda).* 2014; 29(4):265–77. [PubMed: 24985330]
9. Bomberger JM, Barnaby RL, Stanton BA. The deubiquitinating enzyme USP10 regulates the post-endocytic sorting of cystic fibrosis transmembrane conductance regulator in airway epithelial cells. *J Biol Chem.* 2009; 284(28):18778–89. [PubMed: 19398555]
10. Zielenski J. Genotype and Phenotype in Cystic Fibrosis. *Respiration.* 2000; 67:117–133. [PubMed: 10773783]
11. Lee MG, et al. Molecular mechanism of pancreatic and salivary gland fluid and HCO₃ secretion. *Physiol Rev.* 2012; 92(1):39–74. [PubMed: 22298651]
12. Baker JM, et al. CFTR regulatory region interacts with NBD1 predominantly via multiple transient helices. *Nat Struct Mol Biol.* 2007; 14(8):738–45. [PubMed: 17660831]
13. Gadsby DC, Vergani P, Csanady L. The ABC protein turned chloride channel whose failure causes cystic fibrosis. *Nature.* 2006; 440(7083):477–83. [PubMed: 16554808]
14. Hwang TC, Sheppard DN. Gating of the CFTR Cl-channel by ATP-driven nucleotide-binding domain dimerisation. *J Physiol.* 2009; 587(Pt 10):2151–61. [PubMed: 19332488]
15. Chong PA, et al. Dynamics intrinsic to cystic fibrosis transmembrane conductance regulator function and stability. *Cold Spring Harb Perspect Med.* 2013; 3(3):a009522. [PubMed: 23457292]
16. Mense M, et al. In vivo phosphorylation of CFTR promotes formation of a nucleotide-binding domain heterodimer. *EMBO J.* 2006; 25(20):4728–39. [PubMed: 17036051]
17. He L, et al. Multiple membrane-cytoplasmic domain contacts in the cystic fibrosis transmembrane conductance regulator (CFTR) mediate regulation of channel gating. *J Biol Chem.* 2008; 283(39):26383–90. [PubMed: 18658148]
18. Cheung JC, et al. Molecular basis for the ATPase activity of CFTR. *Arch Biochem Biophys.* 2008; 476(1):95–100. [PubMed: 18417076]
19. Ooi CY, Durie PR. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in pancreatitis. *J Cyst Fibros.* 2012; 11(5):355–62. [PubMed: 22658665]
20. Sharer N, et al. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. *N Engl J Med.* 1998; 339(10):645–52. [PubMed: 9725921]
21. Weiss FU, et al. Complete cystic fibrosis transmembrane conductance regulator gene sequencing in patients with idiopathic chronic pancreatitis and controls. *Gut.* 2005; 54(10):1456–60. [PubMed: 15987793]
22. Cohn JA, et al. Increased risk of idiopathic chronic pancreatitis in cystic fibrosis carriers. *Hum Mutat.* 2005; 26(4):303–7. [PubMed: 16134171]
23. Bishop MD, et al. The cystic fibrosis transmembrane conductance regulator gene and ion channel function in patients with idiopathic pancreatitis. *Hum Genet.* 2005; 118(3–4):372–81. [PubMed: 16193325]
24. Noone PG, et al. Cystic fibrosis gene mutations and pancreatitis risk: relation to epithelial ion transport and trypsin inhibitor gene mutations. *Gastroenterology.* 2001; 121(6):1310–9. [PubMed: 11729110]
25. Masson E, et al. A conservative assessment of the major genetic causes of idiopathic chronic pancreatitis: data from a comprehensive analysis of PRSS1, SPINK1, CTFR and CFTR genes in 253 young French patients. *PLoS One.* 2013; 8(8):e73522. [PubMed: 23951356]
26. Rosendahl J, et al. CFTR, SPINK1, CTFR and PRSS1 variants in chronic pancreatitis: is the role of mutated CFTR overestimated? *Gut.* 2013; 62(4):582–92. [PubMed: 22427236]

27. LaRusch J, et al. Mechanisms of CFTR functional variants that impair regulated bicarbonate permeation and increase risk for pancreatitis but not for cystic fibrosis. *PLoS Genet.* 2014; 10(7):e1004376. [PubMed: 25033378]
28. Chu CS, et al. Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. *Nat Genet.* 1993; 3(2):151–6. [PubMed: 7684646]
29. Cuppens H, et al. Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. *J Clin Invest.* 1998; 101(2):487–96. [PubMed: 9435322]
30. Groman JD, et al. Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. *Am J Hum Genet.* 2004; 74(1):176–9. [PubMed: 14685937]
31. Arduino C, et al. Polyvariant mutant CFTR genes in patients with chronic pancreatitis. *Clin Genet.* 1999; 56(5):400–4. [PubMed: 10668931]
32. Steiner B, et al. Common CFTR haplotypes and susceptibility to chronic pancreatitis and congenital bilateral absence of the vas deferens. *Hum Mutat.* 2011; 32(8):912–20. [PubMed: 21520337]
33. Bertin C, et al. Pancreas divisum is not a cause of pancreatitis by itself but acts as a partner of genetic mutations. *Am J Gastroenterol.* 2012; 107(2):311–7. [PubMed: 22158025]
34. Snouwaert JN, et al. An animal model for cystic fibrosis made by gene targeting. *Science.* 1992; 257(5073):1083–1088. [PubMed: 1380723]
35. Clarke LL, et al. Defective epithelial chloride transport in a gene-targeted mouse model of cystic fibrosis. *Science.* 1992; 257(5073):1125–1128. [PubMed: 1380724]
36. Gray MA, et al. CFTR and calcium-activated chloride currents in pancreatic duct cells of a transgenic CF mouse. *Am J Physiol.* 1994; 266(1 Pt 1):C213–C221. [PubMed: 7508188]
37. Olivier AK, Gibson-Corley KN, Meyerholz DK. Animal models of gastrointestinal and liver diseases. Animal models of cystic fibrosis: gastrointestinal, pancreatic, and hepatobiliary disease and pathophysiology. *Am J Physiol Gastrointest Liver Physiol.* 2015; 308(6):G459–71. [PubMed: 25591863]
38. Rogers CS, et al. Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. *Science.* 2008; 321(5897):1837–1841. [PubMed: 18818360]
39. Abu-El-Haija M, et al. Pancreatic damage in fetal and newborn cystic fibrosis pigs involves the activation of inflammatory and remodeling pathways. *Am J Pathol.* 2012; 181(2):499–507. [PubMed: 22683312]
40. Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac disease: Clinical and pathological study. *Am J Dis Child.* 1938; 56:344–399.
41. Uc A, et al. Glycaemic regulation and insulin secretion are abnormal in cystic fibrosis pigs despite sparing of islet cell mass. *Clin Sci (Lond).* 2015; 128(2):131–42. [PubMed: 25142104]
42. Kopelman H, et al. Pancreatic fluid secretion and protein hyperconcentration in cystic fibrosis. *N Engl J Med.* 1985; 312(6):329–334. [PubMed: 3969086]
43. Uc A, et al. Pancreatic and biliary secretion are both altered in cystic fibrosis pigs. *Am J Physiol Gastrointest Liver Physiol.* 2012; 303(8):G961–8. [PubMed: 22936270]
44. Sun X, et al. Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis. *J Clin Invest.* 2010; 120(9):3149–60. [PubMed: 20739752]
45. Olivier AK, et al. Abnormal endocrine pancreas function at birth in cystic fibrosis ferrets. *J Clin Invest.* 2012; 122(10):3755–68. [PubMed: 22996690]
46. Navis A, Bagnat M. Loss of cftr function leads to pancreatic destruction in larval zebrafish. *Dev Biol.* 2015; 399(2):237–48. [PubMed: 25592226]
47. Kristidis P, et al. Genetic determination of exocrine pancreatic function in cystic fibrosis. *Am J Hum Genet.* 1992; 50(6):1178–84. [PubMed: 1376016]
48. Shwachman H, Lebenthal E, Khaw KT. Recurrent acute pancreatitis in patients with cystic fibrosis with normal pancreatic enzymes. *Pediatrics.* 1975; 55(1):86–95. [PubMed: 1110867]
49. Durno C, et al. Genotype and phenotype correlations in patients with cystic fibrosis and pancreatitis. *Gastroenterology.* 2002; 123(6):1857–64. [PubMed: 12454843]

50. Ooi CY, et al. Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis. *Gastroenterology*. 2011; 140(1):153–61. [PubMed: 20923678]
51. Wilschanski M, et al. Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. *Am J Respir Crit Care Med*. 2006; 174(7):787–94. [PubMed: 16840743]
52. Huang W, et al. Fatty acid ethyl ester synthase inhibition ameliorates ethanol-induced Ca²⁺-dependent mitochondrial dysfunction and acute pancreatitis. *Gut*. 2014; 63(8):1313–24. [PubMed: 24162590]
53. Maleth J, et al. Alcohol disrupts levels and function of the cystic fibrosis transmembrane conductance regulator to promote development of pancreatitis. *Gastroenterology*. 2015; 148(2): 427–39. e16. [PubMed: 25447846]
54. Judak L, et al. Ethanol and its non-oxidative metabolites profoundly inhibit CFTR function in pancreatic epithelial cells which is prevented by ATP supplementation. *Pflugers Arch*. 2014; 466(3):549–62. [PubMed: 23948742]
55. Yamamoto A, et al. Ethanol induces fluid hypersecretion from guinea-pig pancreatic duct cells. *J Physiol*. 2003; 551(Pt 3):917–26. [PubMed: 12847207]
56. Criddle DN, et al. Fatty acid ethyl esters cause pancreatic calcium toxicity via inositol trisphosphate receptors and loss of ATP synthesis. *Gastroenterology*. 2006; 130(3):781–93. [PubMed: 16530519]
57. Criddle DN, et al. Ethanol toxicity in pancreatic acinar cells: mediation by nonoxidative fatty acid metabolites. *Proc Natl Acad Sci U S A*. 2004; 101(29):10738–43. [PubMed: 15247419]
58. Takacs T, et al. Intraductal acidosis in acute biliary pancreatitis. *Pancreatology*. 2013; 13(4):333–5. [PubMed: 23890129]
59. Venglovecz V, et al. Effects of bile acids on pancreatic ductal bicarbonate secretion in guinea pig. *Gut*. 2008; 57(8):1102–12. [PubMed: 18303091]
60. Ignath I, et al. CFTR expression but not Cl-transport is involved in the stimulatory effect of bile acids on apical Cl-/HCO₃-exchange activity in human pancreatic duct cells. *Pancreas*. 2009; 38(8): 921–9. [PubMed: 19752774]
61. Maleth J, et al. Non-conjugated chenodeoxycholate induces severe mitochondrial damage and inhibits bicarbonate transport in pancreatic duct cells. *Gut*. 2011; 60(1):136–8. [PubMed: 20732916]
62. Wittel UA, et al. Cigarette smoke-induced differential expression of the genes involved in exocrine function of the rat pancreas. *Pancreas*. 2006; 33(4):364–70. [PubMed: 17079941]
63. Kadiyala V, et al. Cigarette smoking impairs pancreatic duct cell bicarbonate secretion. *JOP*. 2013; 14(1):31–8. [PubMed: 23306332]
64. Bagheri-Hanson A, et al. Intestinal current measurement versus nasal potential difference measurements for diagnosis of cystic fibrosis: a case-control study. *BMC Pulm Med*. 2014; 14:156. [PubMed: 25280757]
65. Raju SV, et al. Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator function. *Am J Respir Crit Care Med*. 2013; 188(11):1321–30. [PubMed: 24040746]
66. Raju SV, et al. Impact of heterozygote CFTR mutations in COPD patients with chronic bronchitis. *Respir Res*. 2014; 15:18. [PubMed: 24517344]
67. Hassan F, et al. Accumulation of metals in GOLD4 COPD lungs is associated with decreased CFTR levels. *Respir Res*. 2014; 15:69. [PubMed: 24957904]
68. Rab A, et al. Cigarette smoke and CFTR: implications in the pathogenesis of COPD. *Am J Physiol Lung Cell Mol Physiol*. 2013; 305(8):L530–41. [PubMed: 23934925]
69. Gould NS, et al. CFTR is the primary known apical glutathione transporter involved in cigarette smoke-induced adaptive responses in the lung. *Free Radic Biol Med*. 2012; 52(7):1201–6. [PubMed: 22266045]
70. Clunes LA, et al. Cigarette smoke exposure induces CFTR internalization and insolubility, leading to airway surface liquid dehydration. *FASEB J*. 2012; 26(2):533–45. [PubMed: 21990373]
71. Lambert JA, et al. Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis. *Am J Respir Cell Mol Biol*. 2014; 50(3): 549–58. [PubMed: 24106801]

72. Sloane PA, et al. A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease. *PLoS One*. 2012; 7(6):e39809. [PubMed: 22768130]
73. Dimagno MJ, et al. A proinflammatory, antiapoptotic phenotype underlies the susceptibility to acute pancreatitis in cystic fibrosis transmembrane regulator (–/–) mice. *Gastroenterology*. 2005; 129(2):665–81. [PubMed: 16083720]
74. DiMugno MJ, et al. Inhibition of acinar apoptosis occurs during acute pancreatitis in the human homologue DeltaF508 cystic fibrosis mouse. *Am J Physiol Gastrointest Liver Physiol*. 2010; 299(2):G400–12. [PubMed: 20522641]
75. Pallagi P, et al. The role of pancreatic ductal secretion in protection against acute pancreatitis in mice*. *Crit Care Med*. 2014; 42(3):e177–88. [PubMed: 24368347]
76. Ko SB, et al. Corticosteroids correct aberrant CFTR localization in the duct and regenerate acinar cells in autoimmune pancreatitis. *Gastroenterology*. 2010; 138(5):1988–96. [PubMed: 20080093]
77. Ko SB, et al. Molecular mechanisms of pancreatic stone formation in chronic pancreatitis. *Front Physiol*. 2012; 3:415. [PubMed: 23133422]
78. Sarles H, et al. Observations on 205 confirmed cases of acute pancreatitis, recurring pancreatitis, and chronic pancreatitis. *Gut*. 1965; 6(6):545–59. [PubMed: 5857891]
79. Allen-Mersh TG. What is the significance of pancreatic ductal mucinous hyperplasia? *Gut*. 1985; 26(8):825–33. [PubMed: 4018649]
80. Hegyi P, Petersen OH. The exocrine pancreas: the acinar-ductal tango in physiology and pathophysiology. *Rev Physiol Biochem Pharmacol*. 2013; 165:1–30. [PubMed: 23881310]
81. Alton EW, et al. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. *Lancet Respir Med*. 2015
82. Kerem B, Chiba-Falek O, Kerem E. Cystic fibrosis in Jews: frequency and mutation distribution. *Genet Test*. 1997; 1(1):35–9. [PubMed: 10464623]
83. Hermann T. Aminoglycoside antibiotics: old drugs and new therapeutic approaches. *Cell Mol Life Sci*. 2007; 64(14):1841–52. [PubMed: 17447006]
84. Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. *Nat Med*. 1996; 2(4):467–9. [PubMed: 8597960]
85. Bedwell DM, et al. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. *Nat Med*. 1997; 3(11):1280–4. [PubMed: 9359706]
86. Wilschanski M, et al. A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. *Am J Respir Crit Care Med*. 2000; 161(3 Pt 1):860–5. [PubMed: 10712334]
87. Wilschanski M, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. *N Engl J Med*. 2003; 349(15):1433–41. [PubMed: 14534336]
88. Clancy JP, et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. *Am J Respir Crit Care Med*. 2001; 163(7):1683–92. [PubMed: 11401894]
89. Sermet-Gaudelus I, et al. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study. *BMC Med*. 2007; 5:5. [PubMed: 17394637]
90. Linde L, et al. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. *J Clin Invest*. 2007; 117(3):683–92. [PubMed: 17290305]
91. Welch EM, et al. PTC124 targets genetic disorders caused by nonsense mutations. *Nature*. 2007; 447(7140):87–91. [PubMed: 17450125]
92. Du M, et al. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. *Proc Natl Acad Sci U S A*. 2008; 105(6):2064–9. [PubMed: 18272502]
93. Kerem E, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. *Lancet*. 2008; 372(9640):719–27. [PubMed: 18722008]

94. Sermet-Gaudelus I, et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. *Am J Respir Crit Care Med*. 2010; 182(10):1262–72. [PubMed: 20622033]
95. Wilschanski M, et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. *Eur Respir J*. 2011; 38(1):59–69. [PubMed: 21233271]
96. Kerem E, et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet Respir Med*. 2014; 2(7):539–47. [PubMed: 24836205]
97. Pedemonte N, et al. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. *J Clin Invest*. 2005; 115(9):2564–71. [PubMed: 16127463]
98. Varga K, et al. Enhanced cell-surface stability of rescued DeltaF508 cystic fibrosis transmembrane conductance regulator (CFTR) by pharmacological chaperones. *Biochem J*. 2008; 410(3):555–64. [PubMed: 18052931]
99. Wainwright CE, et al. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. *N Engl J Med*. 2015; 373(3):220–31. [PubMed: 25981758]
100. Van, Goor F., et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. *Proc Natl Acad Sci U S A*. 2009; 106(44):18825–30. [PubMed: 19846789]
101. Ramsey BW, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. *N Engl J Med*. 2011; 365(18):1663–72. [PubMed: 22047557]
102. De, Boeck K., et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. *J Cyst Fibros*. 2014; 13(6):674–80. [PubMed: 25266159]
103. De, Boeck K., et al. Pancreatitis among patients with cystic fibrosis: correlation with pancreatic status and genotype. *Pediatrics*. 2005; 115(4):e463–9. [PubMed: 15772171]
104. Gerasimenko JV, et al. Ca²⁺ release-activated Ca²⁺ channel blockade as a potential tool in antipancreatitis therapy. *Proc Natl Acad Sci U S A*. 2013; 110(32):13186–91. [PubMed: 23878235]
105. Mu TW, Fowler DM, Kelly JW. Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis. *PLoS Biol*. 2008; 6(2):e26. [PubMed: 18254660]
106. Balch WE, Roth DM, Hutt DM. Emergent properties of proteostasis in managing cystic fibrosis. *Cold Spring Harb Perspect Biol*. 2011; 3(2)
107. Van, Goor F., et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. *Proc Natl Acad Sci U S A*. 2011; 108(46):18843–8. [PubMed: 21976485]
108. Ren HY, et al. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1. *Mol Biol Cell*. 2013; 24(19):3016–24. [PubMed: 23924900]
109. Okiyonedá T, et al. Mechanism-based corrector combination restores DeltaF508-CFTR folding and function. *Nat Chem Biol*. 2013; 9(7):444–54. [PubMed: 23666117]
110. Van Goor F, et al. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. *J Cyst Fibros*. 2014; 13(1):29–36. [PubMed: 23891399]

Figure 1. Schematic structure of CFTR

The CFTR Cl⁻ channel consists of two homologous halves, each containing a hexa-helical membrane spanning domain (MSD1 and MSD2) and a nucleotide binding domain (NBD1 and NBD2). The two halves are connected by the R domain.

Figure 2. Biosynthesis and maturation of CFTR

Only a fraction of newly synthesized and cotranslationally core-glycosylated channels undergoes conformational maturation in the endoplasmic reticulum (ER). The natively folded channel is then transferred by vesicular transport to the *cis/medial*-Golgi, where CFTR is complex-glycosylated before being delivered to the plasma membrane (PM). Unfolded CFTR, similar to other damaged proteins, is rapidly removed from the PM upon ubiquitination by the PM quality control (QC) system. CFTR ubiquitination accelerates internalization, impedes recycling and facilitates preferential sorting towards lysosomal degradation. The six major classes of mutations are highlighted in yellow and treatment options in green.

Figure 3. Mechanism of transepithelial fluid secretion in the gastrointestinal tract

In epithelial tissues CFTR is usually expressed on the apical PM mediating the rate-limiting step for anion (chloride and bicarbonate) secretion, which ultimately controls transepithelial fluid secretion and hence hydration of the luminal surface. During electrogenic Cl^- secretion, Cl^- is transported into the cells via the basolateral membrane by the $\text{Na}^+/\text{K}^+/\text{2Cl}^-$ cotransporter that is followed by the Cl^- transport through the apical membrane via the CFTR channel.

Figure 4. Regulation of CFTR gating

CFTR gating is regulated by the R domain which contains multiple PKA and PKC phosphorylation sites and which physically interacts with NBD1. CFTR uses the energy of ATP binding and hydrolysis to drive ligand-induced conformational changes in the protein that lead to the regulated opening and closing (gating) of the channel 'pore'.

Figure 5. CFTR dysfunction in pancreatitis

Under physiological conditions (left) CFTR (red) is expressed on the luminal membrane of small inter/intralobular pancreatic ducts with the SLC26A6 $\text{Cl}^-/\text{HCO}_3^-$ exchanger (yellow). This expression and the close connection of the two proteins are required for the maintenance of the alkaline luminal pH. During acute pancreatitis (middle) the function of CFTR is inhibited and its expression is decreased leading to impaired bicarbonate and fluid secretion and consequently decreased luminal pH. The washout of the activated digestive enzymes is insufficient. Overall, these changes together will increase the severity of acute pancreatitis. In chronic or autoimmune pancreatitis (right), CFTR expression is markedly

decreased leading to the described consequences. The more viscous, protein-rich ductal fluid promotes the formation of intraluminal protein plugs. The intraductal obstruction will result in pancreatic atrophy and exocrine pancreatic insufficiency.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1

The effect of CFTR mutations on the risk for chronic pancreatitis.

CFTR alleles	Pancreatitis risk	Examples
severe / mild	high risk, causative	p.F508del / p.R117H
mild / mild	likely high risk	p.R117H / p.R117H
severe / -	low risk, 2.5-fold	p.F508del / -
mild / -	low risk, 4-fold	p.R117H / -
non-CF causing	no risk	p.R75Q, p.L997F
T5	no risk	
TG12	no risk	
T5-TG12	limited data	

Table 2

Characteristics of Pancreatic Lesions in CF Animal Models and Humans

	<i>In utero</i>	Birth	Juvenile/Adult
Mouse	Unknown	No or minimal disease; high mortality at weaning if intestinal obstruction is left untreated	No or minimal disease
Rat	Unknown	Unknown, but probably normal	Normal pancreas histology at 22–44 days of age
Pig	Inflammation, dilated acini/ducts with zymogen-like periodic acid-Schiff (PAS)–positive material, acinar cell loss	Acinar atrophy progresses; acini/ducts are filled with zymogen-like material; duct cell proliferation, mucus cell metaplasia, increased loose connective tissue; normal islet morphology but abnormal glycemic response and decreased insulin secretion; high mortality from meconium ileus and intestinal obstruction/perforation, ameliorated in gut-corrected animals	Acinar cell loss, dilated ducts with inspissated material, duct cell proliferation, mucus cell metaplasia, fatty infiltration and fibrosis; normal islet morphology but animals develop spontaneous hyperglycemia
Ferret	Unknown	Minimal disease; dilation of most acini and ductules with inspissated, eosinophilic zymogen secretions, no inflammation; high mortality from intestinal disease, gut-corrected CF ferrets are available	Rapid destruction of the pancreas with progressive inflammation, acinar atrophy, fibrosis, islet cell loss
Zebrafish	Not applicable	Acinar cell loss starts at 14–16 days post-fertilization (dpf), neutrophil infiltration is present and seems to have an impact on acinar damage, high mortality	Acinar atrophy, duct dilatation with PAS-positive material, fibrosis; disorganized islets appearing smaller and more numerous than those in wild-type
Humans	Pancreatic phenotype correlates with the severity of <i>CFTR</i> mutation. First lesions identified ~ 17 weeks of gestation as deposits of PAS-positive material within some acini and ductules. Pancreatic lesions progress to include degeneration of acinar cells and lack of zymogen granules, dilatation of acini and ducts filled with inspissated PAS-positive material and ductular proliferation. Inflammation is mild to moderate. Islets are normal morphologically.	Depending on the severity of <i>CFTR</i> mutation, pancreatic lesions progress to acinar atrophy, fatty infiltration and fibrosis	Depending on the severity of <i>CFTR</i> mutation, pancreatic lesions progress to acinar atrophy, fatty infiltration and fibrosis. Partial islet cell loss is a late finding. With increased age, CF-related diabetes develops. Life expectancy is ~37 years.

Table 3

Clinical trials in CF (Class I mutations)

	Type of administration	Type of study	Results	References
Gentamicin	nose drops	pilot	- significant improvement of NPD	82
		double-blind, placebo-controlled	- significant improvements of NPD and chloride secretion compared with placebo. positive immuno-fluorescent staining in the treatment group. - specific for patients with Class I mutations with no effect in the control group of patients homozygous for the p.F508del mutation. - vast majority of patients with PTCs expressed at least one copy of the p.W1282X CFTR mutation	83
	intravenous	pilot	- significant improvement of NPD	84
		pilot	- significant improvement of NPD in CF patients carrying the p.Y122X mutation	85
Ataluren	oral	phase II clinical trial	- two consecutive 28-day cycles, each of 14 days of treatment followed by 14 days of washout. - significant improvement of NPD -modest but statistically significant improvements in lung function and bodyweight	89
		open label extension study	- NPD improvements were reported over time in both the higher and lower dose treatment groups including 4 patients who did not respond to ataluren in the 2 week study (see above) - modest improvements in pulmonary function and a significant reduction in quantitative cough assessment	90
		phase II clinical trial	-significant improvement in NPD and nasal epithelial CFTR protein by immunofluorescence	91
		phase III clinical trial	- disappointing results, no difference in FEV ₁ between the ataluren and placebo groups. <u>In patients not receiving chronic inhaled tobramycin:</u> - the mean pulmonary exacerbation rate was 40% lower in the ataluren arm. - similar difference in mean relative change from baseline in % predicted FEV ₁ at week 48 was 5.7% favoring ataluren with a mean change from baseline of -0.7% in the ataluren arm, and -6.4% in the placebo arm was observed <u>In patients who received chronic inhaled tobramycin:</u> - no significant difference in mean relative change from baseline in % predicted FEV ₁ at week 48 between ataluren and placebo. <u>In patients who received other antibiotics (eg, colistin and aztreonam):</u> no modification in the treatment effect of ataluren	92